Immunovia Investor DayLund, SwedenJune 30, 2020
2
Forward Looking Statements
IMPORTANT: The following applies to this document, the oral presentation of the information in this document by Immunovia AB (publ) (the “Company”) or any person on behalf of the Company, and any question-and-answer session that follows the oral presentation (collectively, the “Information”).
The Information has been prepared and issued by the Company solely for use at the presentation held by the Company in relation to the Company’s operations and position. The Information has not been independently verified and will not be updated. Unless otherwisestated, and any market data used in the Information is not attributed to a specific source, are estimates of the Company, and have not been independently verified. The Information, including but not limited to forward-looking statements, applies only as of the date of this document and is not intended to give any assurances as to future results.
THE INFORMATION IS BEING MADE AVAILABLE TO EACH RECIPIENT SOLELY FOR ITS INFORMATION AND BACKGROUND.
The Information does not constitute or form part of, and should not be construed as an offer or the solicitation of an offer to subscribe for or purchase any securities issued by the Company.
The Information contains forward-looking statements. All statements other than statements of historical fact included in the Information are forward-looking statements. Forward-looking statements give the Company’s current expectations and projections relating to its financial condition, results of operations, plans, objectives, future performance and business. These statements may include, without limitation, any statements preceded by, followed by or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could” and other words and terms of similar meaning or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Company’s control that could cause the Company’s actual results, performance or achievements to be materiallydifferent from the expected results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Company’s present and future business strategies and the environment in which it will operate in the future. The Company disclaims any obligation to update or revise any forward-lookingstatements, whether as a result of new information, future events or otherwise.
3
Immunovia Investor Day Agenda
IntroductionJulie Silber Director of Investor Relations
Carl Borrebaeck Founder & Chairman of the Board
The Market & IMMray™ Platform Mats Grahn Chief Executive Officer
Road To MarketOur Strategy
Laura Chirica Chief Commercial Officer
Building Sales CLIA/CAP
Michael Pettigrew Senior VP Sales North America
Thomas King, M.D. Medical Director
Conclusion Mats Grahn Chief Executive Officer
Q&A
Mats Grahn Chief Executive Officer
4
Founder & Chairman of the Board
Carl BorrebaeckCEO
Mats Grahn
Welcome & Introduction
5
CEO
IMMrayTM Platform and Market Overview
Mats Grahn
6
Early Detection Of Pancreatic Cancer
Significant Unmet Medical Need
4.6 Months Median SurvivalSomeone Diagnosed With Pancreatic
Cancer In Europe
Today >80% Late Diagnosis Early Diagnosis In Pancreatic Cancer Is The Only Hope
~50% <5% Five Year Survival
7
3 High Risk Groups
Pancreatic Cancer
• Familial autosomal ≥ 2 close fam members
• Familiar non-autosomal ≥ 3 close fam members
• BRCA1/2 Hereditary• FAMMM p16, CDKN2A• Peutz Jeghers• Lynch Syndrome• Hereditary pancreatitis• 2-132 risk of developing
pancreatic cancer
• Depression• Indigestion/Nausea• Jaundice• Mid back pain• Upper abdominal pain• Pain on eating• Fatigue• Unexplained weight loss• Diabetes
• New onset diabetes type II after 50 years of age
• 8-10 times increased risk of developing pancreatic cancer 1-3 year after diagnosis
Early symptoms
Hereditary Familial NOD
8
Initial Addressable Market in EU/US: ~$4.4bn (USD)
IMMray™ Targets A Large Growing Market
Hereditary Early symptoms New Onset Diabetes over 50years of age
• 200,000 patients• 2 tests / year• 600 USD / test
• >3 million new patients / year• 1 test / year in 2 years• 600 USD / test
• 1 million new patients / year• 1 test / patient• 600 USD / test
Pancreatic Cancer Risk Groups
$240M$600M
$3,600M
9
Patient Sample Testing In The Lab
IMMray™ Platform
10
Patent Summary
Pancreatic Cancer Patent Portfolio
PDAC-I filed 25 Mar 2008
PDAC-II
PDAC-III
PDAC-IV
PDAC-V
PDAC-VIfiled 5 Mar 2012
filed 11 Nov 2014
filed 22 Sep 2016
PDAC-VII
filed 10 May 2017
filed 31 Jan 2018
will be filed early July 2020
11
Lund, Sweden
State-of-the-Art Production Facility
12
Immunovias vision is to dominate the pancreatic cancer diagnostics market
Summary
• First to a 4 BUSD Market• Fully Funded Commercial Rollout • Target a Long Term 30% Market Share
13
Chief Commercial Officer
Road to Market
Laura Chirica
14
Immunovia Chief Commercial Officer
Laura Chirica, PhD
Career Highlights:• Global Monoclonal Antibody Purification Program Manager,
BioProcess, GE Healthcare, Uppsala, Sweden• Talent Management mentee for future great leaders, GE Mentorship
Program• Global Marketing Director Agilent Technologies (“Dako”),
Copenhagen, Denmark
• Purification Technologies Director Sartorius, Göttingen, Germany • VP Wieslab Laboratory Services (private lab) Malmö, Sweden• VP Sales and Marketing Svar Sciences (“Euro Diagnostica”), Sweden• 5 years in Immunovia
+20 years experience in developing and leading successful global
commercial strategies with large marketing, sales, application
support and customer support teams from Europe, US and Asia
BSc in Biotechnology, MSc in Biochemistry and PhD in Biochemistry, Sweden.
15
Timeline
IMMrayTM PanCan–d Road to Market
2016 - 2019 2020-2022 2023-
RETROSPECTIVE /OPTIMIZATION/VALIDATION SELF PAY-SALES
PROSPECTIVE STUDIES REIMBURSED SALES
CONFIRMATORY MARKET EXPANSION STUDIES
IMMray™ PanCan-d Q4 2020
ACCREDITATIONS
16
Main programs
Road to market IMMray™ PanCan-d
Key Opinion Leader
Program
Clinical Studies Program
Target Key Customers in priority geographies
- Reference labs (EU/US)- Cancer Centre Clinicians- Private/Public Centre
Clinicians
Build sales org
Reimbursement
- Guidance Experts- Health Economic Studies- Private/Public Insurance
Marketing &Communication
- Press - Home page- Media- Social media- Events (EU/US)
Patient Organizations
Immunovia Dx Laboratories
17
Main programs
Road to market IMMray™ PanCan-d
Key Opinion Leader
Program
Clinical Studies Program
Target Key Customers in priority geographies
- Reference labs (EU/US)- Cancer Centre Clinicians- Private/Public Centre
Clinicians
Build sales org
Reimbursement
- Guidance Experts- Health Economic Studies- Private/Public Insurance
Marketing &Communication
- Press - Home page- Media- Social media- Events (EU/US)
Patient Organizations
Immunovia Dx Laboratories
18
Over 30 KOLs worldwide, including:
World’s Largest Key Opinion Leader Network US and Europe
Prof. Steve Pereira, London, UK
Prof. Bill Greenhal, Liverpool, UK
Prof. Eithne Costello, Liverpool, UK
Prof. Alfredo Carrato, Madrid, Spain
Prof. J. E. Domínguez Muñoz, Santiago de Compostela, Spain
Prof. Robert Grützmann, Erlangen, Germany
Prof. Mattias Löhr, Stockholm, Sweden
Dr. Svein Olav Bratlie, Gothenburg, Sweden
Dr. Diane Simeone, New York, USA
Prof. Margaret Tempero, San Francisco, USA
Dr. Randall Brand, Pittsburgh, USA
Dr. James Moser, Boston, USA
Dr. James Farrell, Yale New Haven, USA
Dr. George Zogopoulos, Montreal, Canada
Assoc. Prof. Aimee Lucas, New York, USA
Dr. Giles Whalen, Boston, USA
Dr. Bryson Katona, Philadelphia, USA
Dr. Brett Shepard, Oregon, USA
North America Europe
19
Main programs
Road to market IMMray™ PanCan-d
Key Opinion Leader
Program
Clinical Studies Program
Target Key Customers in priority geographies
- Reference labs (EU/US)- Cancer Centre Clinicians- Private/Public Centre
Clinicians
Build sales org
Reimbursement
- Guidance Experts- Health Economic Studies- Private/Public Insurance
Marketing&Communication
- Press - Home page- Media- Social media- Events (EU/US)
Patient Organizations
Immunovia Dx Laboratories
20
Positioning IMMray™ PanCan-d and Supporting Clinical Studies
AsymptomaticHospital Pancreatic Cancer Clinics
Early symptoms
Primary care evaluation
Symptoms and positive imaging
HPB / Gastro clinic
Pancreatic cancer recurrence
HPB / Gastro
PanFAM-1 PanSYM-1 To be addressed
PanDIA-1
Frontline diagnostics / Adjunct diagnostics Disease recurrence monitoring tests
Familial / hereditary
individuals inscreening programs
Familial / hereditary individuals
NOT inscreening
Disease progression
21
>10,000 subjects in three major risk groups for pancreatic cancer
3 Prospective Studies
Umeå University HospitalUmeå, Sweden
Healthcare Regional UppsalaUppsala, Sweden
Karolinska InstituteStockholm, Sweden
Linköping University HospitalLinköping, Sweden
Sahlgrenska University HospitalGothenburg, Sweden
Healthcare Region SkåneSkåne, Sweden
Danish Center for Strategic Research Into Typee 2 Diabetes (DD2) – Letter of Intent Copenhagen, Denmark
University of LiverpoolLiverpool, UK
University College London HospitalLondon, UKUniversity Hospital
Santiago De Compostela, Spain
Ramon y Cajal Institute for Health Research (IRYCIS)
Madrid, Spain
Clínica Universidad de Navarra (CUN)
Navarra, SpainCatalan Institute of Oncology (ICO Hospitalet)Bellvitge Biomedical Research Institute
Barcelona, Spain
Research Institute of the McGill University Health Center (RI-MUHC)Montreal, Canada
Massachusetts General Hospital
Boston, MAUniversity of Massachusetts Boston, MA
Yale University Boston Boston, MA
Beth Israel Deaconess Medical Center (BIDMC
Boston, MA
Columbia University
New York, NYMount Sinai
New York, NY
NYU School of Medicine
New York, NYThe Trustees of the University of PENN
Philadelphia, PA
University of Pittsburg Medical Center
Pittsburg, PA
University of Chicago Medical Center
Chicago, IL
OHSU Knight Cancer Institute Portland
Portland, OR
Stanford UniversityPalo Alto, CA
UCLA Health MedicalLos Angeles, CA
Immunovia leads clinical validation studies with > 10,000 subjects recruited at 27 sites from Europe and the USA covering the three highest risk groups for pancreatic cancer
Study High Risk Group No. of Subjects
Non-specific but concerning symptoms >2,000
Asymptomatic familiar/hereditary >2,000
New onset diabetes type II after the age of 50 6,000
Total >10,000
22
Main programs
Road to market IMMray™ PanCan-d
Key Opinion Leader
Program
Clinical Studies Program
Target Key Customers in priority geographies
- Reference labs (EU/US)- Cancer Centre Clinicians- Private/Public Centre
Clinicians
Build sales org
Reimbursement
- Guidance Experts- Health Economic Studies- Private/Public Insurance
Marketing &Communication
- Press - Home page- Media- Social media- Events (EU/US)
Patient Organizations
Immunovia Dx Laboratories
23
Timeline
Road to Reimbursement
2020-2022 2023-
SELF PAY-SALES
PROSPECTIVE STUDIES
REIMBURSED SALES
CONFIRMATORY MARKET EXPANSION STUDIES FOR COUNTRY SPECIFIC REIMBURSEMENT
IMMray™ PanCan-d Q4 2020
PAYER ENGAGEMENT CONTINUES WITH INTERIM PROSPECTIVE RESULTS
Interim read out
Final read out
PAYER INTERACTION
24
Main programs
Road to market IMMray™ PanCan-d
Key Opinion Leader
Program
Clinical Studies Program
Target Key Customers in priority geographies
- Reference labs (EU/US)- Cancer Centre Clinicians- Private/Public Centre
Clinicians
Build sales org
Reimbursement
- Guidance Experts- Health Economic Studies- Private/Public Insurance
Marketing &Communication
- Press - Home page- Media- Social media- Events (EU/US)
Patient Organizations
Immunovia Dx Laboratories
25
Global Collaboration With PancreaticCancer Patient Organizations
Canada: Pancreatic Cancer Canada
US:Lustgarten FoundationThe Pancreatic Cancer Action Network (PanCAN)The World Pancreatic Cancer CoalitionThe Ron Foley FoundationThe Griffith Family FoundationThe MA Pancreatic Cancer AllianceThe Marino/Connolly FoundationPurple Iris FoundationKenner Family Research FundFORCE (Facing Our Risk of Cancer Empowered)Families Fighting Pancreatic Cancer
Sweden: PalemaNätverket mot cancer
Norway:Pancreaskreft Nettverk
Denmark:Pancreasnetværket
Germany:TEB e. V. SelbsthilfeAdP, der Arbeitskreis der Pankreatektomierten e. V.UK:Pancreatic Cancer Action UKPCUK - Pancreatic Cancer UKCancer Research UK (CRUK)Pancreatic Cancer Research Fund (PCRF)MacMillan Cancer Support
Spain:ACANPANGEPAC
Japan:PanCAN Japan
26
Main programs
Road to market IMMray™ PanCan-d
Key Opinion Leader
Program
Clinical Studies Program
Target Key Customers in priority geographies
- Reference labs (EU/US)- Cancer Centre Clinicians- Private/Public Centre
Clinicians
Build sales org
Reimbursement
- Guidance Experts- Health Economic Studies- Private/Public Insurance
Marketing & Communication
- Press - Home page- Media- Social media- Events (EU/US)
Patient Organizations
Immunovia Dx Laboratories
27
Primary Message
IMMray™ PanCan-d test takes a snapshot of an individual’s immune
response in the early stages of pancreatic cancer when resection of
tumour and treatment is possible. 5-year survival rate 5-9%
When PDAC diagnosed in resectablestages
Today 80% PDAC diagnosed in late stages
5-year survival rate upto 50%
Early Diagnosis Saves Lives
28
IMMray™ PanCan-d
Early Detection Targets
Symptomatic patients Gastroenterologist
Patients
Asymptomatic familial
surveillance
New onset diabetes, 50+ years
GP / PCP
CT Scan CT positive
EUS
MRI
CT positiveMRI / EUS positive
CT positiveMRI / EUS positive
CT positiveMRI positive
EUS negative
CT positiveMRI negative EUS negative
Follow up
Follow up
Surgeon
Further investigation
Emergency
Genetic Counselor
29
Reaching PDAC risk groups and clinicians
IMMray™ PanCan-d Virtual / Digital Launch Plan
IMMray™ PanCan-d
Virtual/Digital Launch
Events
Launch and Learn
Online Channels
Communication
Advertising Online Launch
Campaign
Sales Tools
Livestream Launch Day
Event
1
2
3
4
5
6
30
“Around The World For Awareness Of Pancreatic Cancer”
Virtual Walk Events
Main Goal‘Walking Together Around The World’ Will Bring Together Risk Group Individuals, Patients And Their Families To
Raise Awareness Of Pancreatic Cancer and IMMray™ PanCan-d Launch In Q4 2020
Secondary Goals• Cover together 40 075 km from 19 July
2020 to • 19 November 2020- World Pancreatic
Cancer Day • Boost our online presence for the launch• Provide the details to order IMMray™
PanCan-d
1
31
Virtual Events
Examples: • European Pancreatic Club gone digital: 2 July 2020,
Immunovia E-Symposium presentation about latest results and Q4 2020 launch
• Pri-Med Virtual Industry Theatres for primary care doctors, USA• Sept and Dec, Immunovia organizing workshops
• Patient organizations virtual walks support from Immunovia
Main GoalTo Present The Results Of The Final Validation Studies For Clinicians
To Make Them Aware About The Availability Of The Test
1
32
Virtual Launch and Learn
Concept:• KOL presentations• Recorded content, Q&A
live• Start Q3 and continue for
12-18 months
Main GoalTo create sales leads at targeted priority hospitals
2
33
Digital Communication
Communication Tool Target Audience
Podcasts/Interviews Gastro Clinicians, Surgeons, Primary Care Doctors, Genetic Counsellors, Patients And Their Families
Online TV And Radio Patients And Their Families
Online Advertising In Relevant Journals Gastro Clinicians, Surgeons, Primary Care Doctors, Genetic Counsellors
Main GoalTo Create Awareness About The Availability Of IMMray™ PanCan-d
3
34
Awareness of launch Q4 2020
Advertising Campaign
Concept• What does early detection mean for
you?• Start Sept until launch in US and
Europe• In collaboration with patients, their
families and clinicians• Distributed via all online channels
Main GoalTo create awareness about the availability of IMMray PanCan-d for all target groups
4
35
Digital Sales Tools
Concept:• Virtual sales training• Virtual selling educational
program
• Virtual sales tools• E- Marketing collaterals • Customer engagement
tracking
Main GoalTo educate sales team with digital tools and how to use digital tools
5
36
Live Stream Digital Launch Event
Launch Day
Concept:• Launch E-conference on the launch
date, in Q4 2020,• Talks and interviews from:
• Survivors/patient orgrepresentative
• KOLs• Immunovia
Main GoalTo create awareness about the availability of IMMray PanCan-d for all target groups
6
37
Main programs
Road to Market IMMray™ PanCan-d
Key Opinion Leader
Program
Clinical Studies Program
Target Key Customers in priority geographies
- Reference labs (EU/US)- Cancer Centre Clinicians- Private/Public Centre
Clinicians
Build sales org
Reimbursement
- Guidance Experts- Health Economic Studies- Private/Public Insurance
Marketing &Communication
- Press - Home page- Media- Social media- Events (EU/US)
Patient Organizations
Immunovia Dx Laboratories
38
IMMray™ PanCan-d
Launch and Commercialization Countries
Countries with prospective site centers, PanFAM, PanSYM, PanDIA, familial pancreatic screening programs, diagnostic/GI centers and private health systems
1st Wave US Commercialization2nd Wave Europe Commercialization
Sweden/NordicUKSpain / ItalyDACHBeneluxFranceCanada
39
Main programs
Road to Market IMMray™ PanCan-d
Key Opinion Leader
Program
Clinical Studies Program
Target Key Customers in priority geographies- Reference labs (EU/US)- Cancer Centre Clinicians- Private/Public Centre
Clinicians
Build sales orgMike Pettigrew
Reimbursement
- Guidance Experts- Health Economic Studies- Private/Public Insurance
Marketing&Communication
- Press - Home page- Media- Social media- Events (EU/US)
Patient Organizations
Immunovia Dx Laboratories
40
Senior VP Sales North America
Road to Market
Michael Pettigrew
Sales Strategy
41
Immunovia Senior Vice President Sales
Michael Pettigrew
Career Highlights• Management of over 500 M USD Revenue per year• Management of over 300 Sales and Support Personnel• Commercialization of AKTA platform of Chromatography Systems• Commercialization of MegaBACE DNA Sequencer
• Acquisition of Microarray platform from Motorola Corp• Divestment of ESA Biosciences from Magellan Corp• Integration of multiple companies, individuals and technologies in multiple
organizations• Responsible for significant revenue and resource growth in multiple organizations
Mr. Pettigrew brings over 30 years of experience and has focused his extensive global expertise in the management of marketing & sales, business and
strategic account development, licensing, mergers & acquisition, and commercial technology platform
development. Has held positions at Thermo Fisher Scientific, Magellan Biosciences, at GE Healthcare (Vice
President, Sales), Amersham (Vice President, Genomics), and Pharmacia (Director of Marketing,
North America).
42
Sales Focus by Clinical Specialty
Symptomatic patients Gastroenterologist
Patients
Asymptomatic familial
surveillance
New onset diabetes, 50+ years
GP / PCP
CT Scan CT positive
EUS
MRI
CT positiveMRI / EUS positive
CT positiveMRI / EUS positive
CT positiveMRI positive
EUS negative
CT positiveMRI negative EUS negative
Follow up
Follow up
Surgeon
Further investigation
Emergency
Genetic Counselor
43
Territory 1 • Gastroenterologists = 1458• 68 Multidisciplinary GI centers• Genetic Counselor = 154
Territory 2 • Gastroenterologists = 2698• 135 Multidisciplinary GI centers• Genetic Counselor = 160
Territory 4 • Gastroenterologist = 2159• 155 Multidisciplinary GI centers• Genetic Counselor = 99
Territory 3 • Gastroenterologist = 2069• 147 Multidisciplinary GI centers• Genetic Counselor= 226
1
2
3
4
By Geography
Sales Implementation Strategy
44
Sales Implementation By Pancreatic Cancer Center
National Pancreas Foundation Accredited Center
Pancreatic Cancer Center
45
Sales Implementation by Priority 1 Hospitals
Yale Center for Pancreatic Disease CTStamford Hospital CTHartford Hospital CTMiddlesex Hospital CT
Beth Israel Deaconess Medical Center MABrigham and Women’s Hospital / Dana Farber Cancer Inst MAMassachusetts General Hospital MALahey Hospital and Medical Center MA
Dartmouth-Hitchcock Medical Center NHUniversity of Vermont Medical Center VTMaine Medical Center MERI Hospital, The Miriam Hospital, Newport Hospital RI
1
46
Targeting Will Be Key
Target Customers Mass General Hospital
Focus on Following:• Pancreatic Specialists• Pancreatic Surgeons• Gastroenterologist• Clinical Geneticists
Populating CRM:• Hospitals• Clinical Target
customers
Endocrinology, Diabetes and Metabolism 31Family Medicine / General Practice 65Gastroenterology 11General Surgery 28Geriatric Medicine 9Hematology & Oncology 28Internal Medicine 164Pediatric Hematology & Oncology 2Total 338
Total Accessible Market (Massachusetts General Hospital)
47
Pancreatic Specialists Mass General
Approximately 30 Pancreatic Specialists • Focus for Sales• Educate all involved in these
practicesSource for additional Target CustomersReference Base
Disorders of The Biliary and Pancreas 1Endocrine Pancreas 1ERCP (Endoscopic Retrograde Cholangiopancreatography) 1Familial Pancreatic Cancer 1Liver and Pancreatic Disorders 1Liver, Biliary and Pancreatic Disease 2Organ Transplantation (Kidney, Liver, And Pancreas) 1Pancreas and Islet Transplant 2Pancreatic and Hepatobiliary 2Pancreatic Biliary Disorders 2Pancreatic Cancer 12Pancreatic Cystic Tumors 3Pancreatic Disease 4Pancreatic Neuroendocrine Tumors 1Pancreatic Transplant 1Pancreatitis (Acute and Chronic) 6Pancreatobiliary Surgery 2Primary Hepatic and Pancreatic Cancers 1
Total 44
Pancreatic Specialists (Massachusetts General Hospital)
48
Sales Organization
CustomerRelationshipManagement
System
FIELD SALES REPRESENTATIVES
INSIDE SALES SUPPORT
Next Steps
49
Based On Population PDAC Incidence Age Distribution
Sales Expansion Principles
1
2
3
46
57
10
8
9
11
Step 1
Step 3
Step 2
Step 1
Step 2
Step 1
Step 3
Step 3
Based on: PopulationPDAC incidenceAge distribution
Step 2
50
Medical Director
Road to Market
Dr. Thomas King
Insight From The Clinical Perspectives
51
Main programs
Road to Market IMMray™ PanCan-d
Key Opinion Leader
Program
Clinical Studies Program
Target Key Customers in priority geographies
- Reference labs (EU/US)- Cancer Centre Clinicians- Private/Public Centre
Clinicians
Build sales org
Reimbursement
- Guidance Experts- Health Economic Studies- Private/Public Insurance
Communication
- Press - Home page- Media- Social media- Events (EU/US)
Patient Organizations
Immunovia Dx Laboratories
52
Immunovia US Laboratory Medical DirectorThomas King, MD, PhD
Career Highlights:Career Highlights:Director, MEDPACE HOLDINGS, INC. (MEDP, NASDAQ)Adjunct Associate Professor, RUTGERS, THE STATE UNIVERSITY OF NEW JERSEYMedical Director, IMMUNOVIAChief of Pathology and Laboratory Medicine, ST. VINCENT
HOSPITAL, Worcester, MA 2013-2017, Partner and Medical Director, UNIVERSITY PATHOLOGISTS, LLCAssociate Professor, BOSTON UNIVERSITY SCHOOL OF MEDICINESenior Director, MILLENNIUM PHARMACEUTICALSAssociate Professor of Pathology and Residency Program Director, BROWN UNIVERSITY SCHOOL OF MEDICINE
Board certified Pathologist with Ph.D. in Molecular Biology and extensive experience as a laboratory director in hospital, academic and corporate settings. MD and PhD, Washington University 1984 Fellow and Inspector, College of American Pathologists Established multiple Molecular Pathology Laboratories with Laboratory Developed Tests (LDTs)
53
Process for CLIA Registration and Accreditation (CAP)
IMMray™ PanCan-d Q4 2020
Train Personnel and Verify or Validate Test Method• Document training and
competence• Verify FDA approved
tests• Validate non-FDA
approved tests (LDT’s)
Apply for MA State License
Accreditation by CAP
SalesStart
Fit Out Lab• Equipment• Personnel• Materials• Supplies
Develop & Approve Procedures/Methods• Use of Equipment• Performance of Lab
Tests (i.e. glucose, IMMray PanDAC)
54
Virtual Tour of Immunovia Dx Lab Marlborough USA and IMMray™ PanCan-d Test
55
Immunovias vision is to dominate the pancreatic cancer diagnostics market
Summary
• First to a 4 BUSD Market• Well Financed Commercial Rollout • Target a Long Term 30% Marketshare
Q & A
57
Development Studies to Market Introduction
Process Overview for Lung Cancer Program
Initial Discovery Study
KOL NetworkBuild network, get expert advice, complete study protocols and make agreements on sample delivery
Sample Delivery & Lab Work Once all the blood samples and clinical data have arrived, lab work is performed using IMMrayTM discovery arrays
Optimization Study (if needed)Optimize candidate commercial signature & algorithm; Full IMMrayTM array
CommercializationProduct launch
Commercial Test Model StudyThe candidate commercial signature and fine tune algorithm
Verification StudyLocked signature and algorithms on known samples
Validation StudyLocked signature and algorithms on blinded samples
08
04
01
02
03
06
07
AnalysisBioinformatic analysis of the study
Discovery Studies
KOL Network & Fresh Blood SamplesTo KOL Network to collect fresh blood samples that mirror the commercial environment
05
Q & A
59
Immunovia Virtual Walk
Let’s Walk, Together,
Around The Globe To Raise Awareness
For Pancreatic Cancer
Interested? Please send us an email at [email protected]
Registration opens 19 July 2020
60
Immunovias vision is to dominate the pancreatic cancer diagnostics market
Summary
• First to a 4 BUSD Market• Well Financed Commercial Rollout • Target a Long Term 30% Market Share
Thank you!
Julie SilberDirector of Investor Relations
Immunovia ABMobile: +46(0)79 3486277
www.immunovia.com